Navigation Links
Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
Date:12/18/2007

/p>

IPLEX(TM) is a complex recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM) is currently being studied as a treatment for several serious medical conditions, including two neuromuscular disorders, Myotonic Muscular Dystrophy (MMD) and ALS (Lou Gehrig's Disease); HIV-Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP).

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may exper
'/>"/>

SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...lif., Nov. 20 Bionovo, I...present results from the Phase 1B,clinical trial ...ic breast,cancer, BZL101, at the Society for Inte... in Atlanta, Georgia. The Company,s oral presenta...ill be presented as a part of the Best of the,SIO...
(Date:11/20/2008)...rway, November 20 The Scandinavian...as announced results of studies on its,lead antim...Washington, DC,the studies showed that the novel...cidal effect, significantly better towards killing... than marketed gold standard drugs. In,addition t...
(Date:11/19/2008)...N.Y., Nov. 19 Biotech scientists i...toxicology research to better understand the effec...systems, reports Genetic Engineering & Biotec...ted in figuring out a new compound,s mechanism of ...cology technique, according to the November 15 iss...
(Date:11/18/2008)...Nov. 18 Arlington Medical Resource...e for the pharmaceutical and diagnostic,imaging i...ing,s Privigen was,sold in the U.S. during the th... of intravenous immune globulin (IVIG) and was lau...duct created from the blood plasma of thousands,o...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 1CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 1Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 3Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 1Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 2Sosei Announces Update on Phase I Trials for SD118 6953 1Sosei Announces Update on Phase I Trials for SD118 6953 2Sosei Announces Update on Phase I Trials for SD118 6953 3
(Date:11/21/2008)...ng may lead to new therapies for preterm labor , ...earchers say they,ve found the switch that activat...dbirth, a finding that may lead to therapies for p...ally binds the protein IP on the surface of these ...tive during pregnancy. , But researchers from ...
(Date:11/21/2008)...al meeting of shareholders to be held on January 8...stCall/ - Med-Emerg International Inc. ("MedEmerg"... of health services, announced today that it has o... Court of Justice concerning its previously announ...nt to which AIM Health Group Inc. ("AIM") will acq...
(Date:11/21/2008)...TON(Nov. 21, 2008)The University of Texas Health S..., Training Excellence in Aging Studies (TEXAS), to...h a prestigious $2 million award from the Donald W...g funds., "This will allow us to teach geriatric ...or medical student to practicing physicians. With ...
(Date:11/21/2008)...AND, Colo., Nov. 21 Hesk...t will present at the New York Society of,Securit...ma Conference on,December 2, 2008 at 1177 Avenue ...resentation is scheduled to begin at 9:35 a.m. Eas...vailable via live webcast and for two weeks,follo...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
... Hospital doctors warn that children playing footb... from blisters caused by football boots // . Acco... toxic shock syndrome in the UK have been attribut...in children. However if misdiagnosed or left untre...
...ch is already running in a loss would have to pay ...s they are not in a position // to fulfil the comm...tem for the health services. The trusts in the so...d 50 full-time employees to help develop the ?20bn...
...radesh has decided to take action against erring P...has now fixed the number of patients //to be treat...y health centres so as to stop the 'popular' pract...eave the hospital early, at least an hour before t...
...as announced at the Cheltenham Science Festival th... mount Everest to conduct //a research into the ef...cientists from the Centre for Aviation, Space and ...nstitute of Human Health and Performance, Universi...
Other Medicine News:Health News:Budding Footballers at Risk from Blood Infection 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:UP Government Fixes Work Schedules for Provincial Medical Service Doctors 2Health News:Mount Everest to be Site of Research into Hypoxia 2
Medical Claims Billing
Managed care is a billing and tracking system.
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information.
HCS INTERACTANT is an integrated healthcare information system. Financial applications include general ledger, accounts payable, human resources and comprehensive management reporting. HCS general fi
Medicine Products: